Ocular Therapeutix Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Across the recent three months, 5 analysts have shared their insights on Ocular Therapeutix (NASDAQ:OCUL), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 4 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.4, a high estimate of $21.00, and a low estimate of $19.00. Observing a 2.0% increase, the current average has risen from the previous average price target of $20.00.
Interpreting Analyst Ratings: A Closer Look
The standing of Ocular Therapeutix among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $21.00 | $21.00 |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $21.00 | $21.00 |
| Serge Belanger | Needham | Maintains | Buy | $20.00 | $20.00 |
| Yi Chen | HC Wainwright & Co. | Raises | Buy | $21.00 | $19.00 |
| Yi Chen | HC Wainwright & Co. | Maintains | Buy | $19.00 | $19.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ocular Therapeutix. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Ocular Therapeutix's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ocular Therapeutix's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Ocular Therapeutix analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Ocular Therapeutix's Background
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix: Financial Performance Dissected
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Ocular Therapeutix's revenue growth over 3M faced difficulties. As of 31 December, 2025, the company experienced a decline of approximately -22.43%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ocular Therapeutix's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -487.95% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.17%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ocular Therapeutix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.61%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ocular Therapeutix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.